These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 15301899)
21. Reassessing the validity of surrogate markers of drug efficacy in the treatment of coronary artery disease. Colatsky TJ Curr Opin Investig Drugs; 2009 Mar; 10(3):239-44. PubMed ID: 19333881 [TBL] [Abstract][Full Text] [Related]
22. Role of magnetic resonance and intravascular magnetic resonance in the detection of vulnerable plaques. Wilensky RL; Song HK; Ferrari VA J Am Coll Cardiol; 2006 Apr; 47(8 Suppl):C48-56. PubMed ID: 16631510 [TBL] [Abstract][Full Text] [Related]
23. Aortic plaque imaging and monitoring atherosclerotic plaque interventions. Momiyama Y; Fayad ZA Top Magn Reson Imaging; 2007 Oct; 18(5):349-55. PubMed ID: 18025989 [TBL] [Abstract][Full Text] [Related]
24. Optimal medical management of peripheral arterial disease. Rice TW; Lumsden AB Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725 [TBL] [Abstract][Full Text] [Related]
25. Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy. Tamargo J; Caballero R; Gómez R; Núñez L; Vaquero M; Delpón E Pharmacol Ther; 2007 Apr; 114(1):107-26. PubMed ID: 17287023 [TBL] [Abstract][Full Text] [Related]
26. The mainstream hypothesis that LDL cholesterol drives atherosclerosis may have been falsified by non-invasive imaging of coronary artery plaque burden and progression. Ware WR Med Hypotheses; 2009 Oct; 73(4):596-600. PubMed ID: 19560285 [TBL] [Abstract][Full Text] [Related]
34. Intravascular ultrasound for the evaluation of therapies targeting coronary atherosclerosis. Böse D; von Birgelen C; Erbel R J Am Coll Cardiol; 2007 Mar; 49(9):925-32. PubMed ID: 17336714 [TBL] [Abstract][Full Text] [Related]
35. Identification and treatment of vulnerable plaque. Nakamura M; Lee DP; Yeung AC Rev Cardiovasc Med; 2004; 5 Suppl 2():S22-33. PubMed ID: 15184831 [TBL] [Abstract][Full Text] [Related]
36. Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: insight from intravascular ultrasonography trials. Sipahi I; Tuzcu EM Am J Cardiovasc Drugs; 2008; 8(6):365-71. PubMed ID: 19159123 [TBL] [Abstract][Full Text] [Related]
37. Utility of biomarkers and imaging in the development of drugs for the treatment of coronary atherosclerosis. Waters DD Can J Cardiol; 2012; 28(6):687-92. PubMed ID: 22626947 [TBL] [Abstract][Full Text] [Related]
38. [Regression of atherosclerotic plaques during treatment with statins]. Kovárník T; Aschermann M Cas Lek Cesk; 2004; 143(10):669-74; discussion 674-5. PubMed ID: 15584615 [TBL] [Abstract][Full Text] [Related]
39. Can intensive statin therapy halt the progression of atherosclerosis? Recent evidence and potential implications for patient management. Kushner PR Prog Cardiovasc Nurs; 2007; 22(4):207-13. PubMed ID: 18059198 [TBL] [Abstract][Full Text] [Related]
40. A direct comparison of intravascular ultrasound and quantitative coronary arteriography: implications for measures of atherosclerosis as clinical surrogates. Brown BG Circulation; 2007 Apr; 115(14):1824-6. PubMed ID: 17420360 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]